Insmed reported $186.38M in Selling and Administration Expenses for its fiscal quarter ending in September of 2025.





Selling And Administration Expenses Change Date
BioMarin Pharmaceutical USD 223.42M 8.86M Sep/2025
Cytokinetics USD 158.75M 93.03M Sep/2025
DBV Technologies USD 3.63M 3.18M Sep/2025
Dynavax Technologies USD 40.09M 1.45M Sep/2025
Gilead Sciences USD 1.35B 6M Sep/2025
Insmed USD 186.38M 109.94M Sep/2025
Novartis USD 3.3B 137M Sep/2025
Regeneron Pharmaceuticals USD 775M 117.2M Dec/2025
Sarepta Therapeutics USD 77.11M 7.22M Sep/2025
Ultragenyx Pharmaceutical USD 86.62M 26K Sep/2025
Vertex Pharmaceuticals USD 445.1M 20.5M Sep/2025